TY - JOUR
T1 - Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on18F-DCFPYL PET/CT imaging
AU - Werner, Rudolf A.
AU - Bundschuh, Ralph A.
AU - Bundschuh, Lena
AU - Javadi, Mehrbod S.
AU - Leal, Jeffrey P.
AU - Higuchi, Takahiro
AU - Pienta, Kenneth J.
AU - Buck, Andreas K.
AU - Pomper, Martin G.
AU - Gorin, Michael A.
AU - Lapa, Constantin
AU - Rowe, Steven P.
N1 - Funding Information:
Funding was provided by the Prostate Cancer Foundation Young Investigator Award; National Institutes of Health grants CA134675, CA183031, CA184228, and EB024495; and the European Union’s Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement 701983. Martin G. Pomper is a coinventor on a patent covering 18F-DCFPyL and is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. He has also received research funding from Progenics Phamaceuticals, the licensee of 18F-DCFPyL. Michael A. Gorin has served as a consultant to, and has received research funding from, Progenics Phamaceuticals. Kenneth J. Pienta has received research funding from Progenics Phamaceuticals. Steven P. Rowe has received research funding from Progenics Phamaceuticals. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)–targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-flu-oro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Methods: Four readers (2 experienced readers (ERs, .3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs,,1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 5018F-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion–based, on an organ-based, and on an overall PSMA-RADS score–based level were computed. Results: The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, $0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) (P 5 0.005). Conclusion: PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.
AB - Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)–targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-flu-oro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Methods: Four readers (2 experienced readers (ERs, .3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs,,1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 5018F-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion–based, on an organ-based, and on an overall PSMA-RADS score–based level were computed. Results: The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, $0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) (P 5 0.005). Conclusion: PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.
KW - F-DCFPyL
KW - Interobserver
KW - Interreader
KW - PSMA
KW - PSMA-RADS
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85057580761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057580761&partnerID=8YFLogxK
U2 - 10.2967/jnumed.118.217588
DO - 10.2967/jnumed.118.217588
M3 - Article
C2 - 30190304
AN - SCOPUS:85057580761
SN - 0161-5505
VL - 59
SP - 1857
EP - 1864
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 12
ER -